Communiqués Cognition Therapeutics, Inc.

Actions

CGTX

US19243B1026

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
1,66 ^USD	-0,60%		-12,63%	-10,27%

07/06	COGNITION THERAPEUTICS, INC. : Chardan Research maintient sa recommandation à l'achat	ZM
29/05	COGNITION THERAPEUTICS, INC. : HC Wainwright relève à l'achat	ZM

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Cognition Therapeutics : CGTX Corporate Deck	13/06	PU
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease	21/05	AQ
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update	07/05	GL
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04	AQ
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's disease	23/04	AQ
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease	22/04	AQ
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference	02/04	GL
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024	01/04	AQ
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update	26/03	GL
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03	GL
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03	AQ
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock	14/03	GL
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock	12/03	GL
Cognition Therapeutics : Results of Operations and Financial Condition - Form 8-K	11/03	PU
Cognition Therapeutics Announces Proposed Public Offering of Common Stock	11/03	GL
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies	06/03	AQ
Cognition Therapeutics to Present at the TD Cowen Health Care Conference	26/02	GL
Cognition Therapeutics to Present at the TD Cowen Health Care Conference	26/02	AQ
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812	06/02	AQ
Cognition Therapeutics CEO Issues Letter to Shareholders	04/01	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Cognition Therapeutics, Inc.

Actions

CGTX

US19243B1026

Communiqués

Filtres